Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02201524 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT02201524 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 59 participants.
The verdict
NCT02201524, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
Study B7451005 is a Phase 2 study which will assess the efficacy and safety of PF-04965842 in patients with moderate to severe psoriasis. The study will include three PF-04965842 groups (200 mg daily, 400 mg daily and 200 mg twice daily) and a placebo group. The treatment period will be 4 weeks in duration and will be followed up by a 4 week follow up period.
Interventions
- OTHER Placebo
- DRUG PF-04965842
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02201524
The ClinicalTrials.gov registry entry for NCT02201524 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02201524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02201524 about?
NCT02201524 is a clinical study titled "Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis". Study B7451005 is a Phase 2 study which will assess the efficacy and safety of PF-04965842 in patients with moderate to severe psoriasis. The study will include three PF-04965842 groups (200 mg daily, 400 mg daily and 200 mg twice daily) and a placebo group. The treatment period will be 4 weeks in d...
What is the current status of trial NCT02201524?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2014-11. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02201524?
The interventions under investigation include: Placebo (OTHER), PF-04965842 (DRUG).
Who is sponsoring clinical trial NCT02201524?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.